Sustained Viral Response to Ipilimumab Treatment in a Patient with HCV Chronic Infection and Metastatic Melanoma： A Case Report  

作　　者：Daniel Eiger Rodrigo Coutinho Mariano Patricia Taranto Daniela Pezzutti Domingues Armentano Rene Claudio Gansl 

机构地区：[1]Centro de Oncologia e Hematologia Einstein Familia Dayan-Daycoval, Hospital lsraelita Albert Einstein, Sao Paulo, 05652-900,Brazil

出　　处：《Journal of Pharmacy and Pharmacology》2017年第5期231-236,共6页药剂与药理学（英文版）

摘　　要：The treatment of metastic melanoma has rapidly evolved in the last 5 years, giving clinicians and patients the hope for long lasting responses. In the field of modern immunotherapy, we are reaching the point of an expressive percentage of patients achieving long term survival with anti-CTLA4 and anti-PD1 checkpoint inhibitors. Of note, there is a considerable amount of patients excluded from the checkpoint blockade trials because of comorbidities like chronic viral infections. A precaution to avoid autoimmune induced hepatitis rendered HBV （hepatitis B virus） and HCV （hepatitis C virus） infected patients usually ineligible, but real life data in those patients, who are getting treatment despite of that, is pointing toward the feasibility and safety of immunotherapy in this context. To ilustrate that, we report the case of a metastatic non-BRAF mutated melanoma patient with HCV chronic infection and a surprising benefit derived from ipilimumab and pembrolizumab for his latter condition.

关 键 词：MELANOMA IMMUNOTHERAPY checkpoint inhibitors IPILIMUMAB pembrolizumab HCV. 

分 类 号：S858.28[农业科学—临床兽医学] Q78[农业科学—兽医学]